Cargando…
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
The aim of the study is to examine the frequency and costs associated with above-label dosing of biologics in patients with psoriatic arthritis (PsA). MarketScan identified adults with ≥1 International Classification of Diseases, Clinical Modification diagnosis for PsA and ≥1 pharmacy claim for biol...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486473/ https://www.ncbi.nlm.nih.gov/pubmed/28474139 http://dx.doi.org/10.1007/s10067-017-3636-3 |
_version_ | 1783246256807608320 |
---|---|
author | Schwartzman, Sergio Li, Yunfeng Zhou, Huanxue Palmer, Jacqueline B. |
author_facet | Schwartzman, Sergio Li, Yunfeng Zhou, Huanxue Palmer, Jacqueline B. |
author_sort | Schwartzman, Sergio |
collection | PubMed |
description | The aim of the study is to examine the frequency and costs associated with above-label dosing of biologics in patients with psoriatic arthritis (PsA). MarketScan identified adults with ≥1 International Classification of Diseases, Clinical Modification diagnosis for PsA and ≥1 pharmacy claim for biologics of interest between January 1, 2011 and December 31, 2013. The first biologic claim was the index date with a 1-year follow-up period and three additional months to confirm continuous biologic use. Exclusion criteria included switching to a different biologic or diagnosis with another autoimmune disease. During the follow-up period, duration was stratified into three groups: <30, 30–179, and ≥180 days of above-label dosing (>10% of the labeled dose). One-tailed t test was conducted to examine the impact of above-label duration on healthcare costs. We identified 4245 PsA patients receiving etanercept (n = 2342), adalimumab (n = 1788), and golimumab (n = 115). Above-label dosing of <30 days (85% adalimumab, 90.4% etanercept, and 95.7% golimumab) and ≥180 days (9.6% adalimumab, 4.1% etanercept, and 2.6% golimumab) was observed. All-cause total healthcare costs for <30 days of above-label use (etanercept $30,625, adalimumab $31,620, and golimumab $37,224), 30–179 days (etanercept $35,602, adalimumab $38,915, and golimumab $64,349), and ≥180 days (etanercept $55,349, adalimumab $54,176, and golimumab $47,993) were reported. Longer above-label duration (30–179 versus <30 days, ≥180 versus 30–179 and ≥180 days) with etanercept or adalimumab was significantly associated with higher mean increased total all-cause healthcare, PsA-specific healthcare, and biologic costs (p < 0.05). Above-label use of anti-TNF biologics does occur and is associated with significantly increased healthcare costs. |
format | Online Article Text |
id | pubmed-5486473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer London |
record_format | MEDLINE/PubMed |
spelling | pubmed-54864732017-07-17 Economic impact of biologic utilization patterns in patients with psoriatic arthritis Schwartzman, Sergio Li, Yunfeng Zhou, Huanxue Palmer, Jacqueline B. Clin Rheumatol Original Article The aim of the study is to examine the frequency and costs associated with above-label dosing of biologics in patients with psoriatic arthritis (PsA). MarketScan identified adults with ≥1 International Classification of Diseases, Clinical Modification diagnosis for PsA and ≥1 pharmacy claim for biologics of interest between January 1, 2011 and December 31, 2013. The first biologic claim was the index date with a 1-year follow-up period and three additional months to confirm continuous biologic use. Exclusion criteria included switching to a different biologic or diagnosis with another autoimmune disease. During the follow-up period, duration was stratified into three groups: <30, 30–179, and ≥180 days of above-label dosing (>10% of the labeled dose). One-tailed t test was conducted to examine the impact of above-label duration on healthcare costs. We identified 4245 PsA patients receiving etanercept (n = 2342), adalimumab (n = 1788), and golimumab (n = 115). Above-label dosing of <30 days (85% adalimumab, 90.4% etanercept, and 95.7% golimumab) and ≥180 days (9.6% adalimumab, 4.1% etanercept, and 2.6% golimumab) was observed. All-cause total healthcare costs for <30 days of above-label use (etanercept $30,625, adalimumab $31,620, and golimumab $37,224), 30–179 days (etanercept $35,602, adalimumab $38,915, and golimumab $64,349), and ≥180 days (etanercept $55,349, adalimumab $54,176, and golimumab $47,993) were reported. Longer above-label duration (30–179 versus <30 days, ≥180 versus 30–179 and ≥180 days) with etanercept or adalimumab was significantly associated with higher mean increased total all-cause healthcare, PsA-specific healthcare, and biologic costs (p < 0.05). Above-label use of anti-TNF biologics does occur and is associated with significantly increased healthcare costs. Springer London 2017-05-04 2017 /pmc/articles/PMC5486473/ /pubmed/28474139 http://dx.doi.org/10.1007/s10067-017-3636-3 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Schwartzman, Sergio Li, Yunfeng Zhou, Huanxue Palmer, Jacqueline B. Economic impact of biologic utilization patterns in patients with psoriatic arthritis |
title | Economic impact of biologic utilization patterns in patients with psoriatic arthritis |
title_full | Economic impact of biologic utilization patterns in patients with psoriatic arthritis |
title_fullStr | Economic impact of biologic utilization patterns in patients with psoriatic arthritis |
title_full_unstemmed | Economic impact of biologic utilization patterns in patients with psoriatic arthritis |
title_short | Economic impact of biologic utilization patterns in patients with psoriatic arthritis |
title_sort | economic impact of biologic utilization patterns in patients with psoriatic arthritis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486473/ https://www.ncbi.nlm.nih.gov/pubmed/28474139 http://dx.doi.org/10.1007/s10067-017-3636-3 |
work_keys_str_mv | AT schwartzmansergio economicimpactofbiologicutilizationpatternsinpatientswithpsoriaticarthritis AT liyunfeng economicimpactofbiologicutilizationpatternsinpatientswithpsoriaticarthritis AT zhouhuanxue economicimpactofbiologicutilizationpatternsinpatientswithpsoriaticarthritis AT palmerjacquelineb economicimpactofbiologicutilizationpatternsinpatientswithpsoriaticarthritis |